Yep, it's all just ramping Nobby. Nothing to see here. |
So it looks like a full scale ramp is ongoing… |
Well I’ve made some good money from Incanthera so perhaps I should now be lauding Tim as a biotech guru…. |
Good lad. You know it makes sense. |
Ok I’ll rush out and buy some then….😆; |
I feel it in my bones Nobby. |
Now might be a good time to buy IMM. |
This is where future funding will come from .... ;-)
GLA SR
The warrant deeds (between the Company and the respective counter-parties - the holders of warrants) have been varied, such that the exercise price of the 2021 Warrants and 2022 Warrants is reduced from 11 pence and 5.5 pence respectively to 2 pence.
The 2021 Warrants and 2022 Warrants will then be exercisable at the earlier of (i) the five day volume weighted average price of Ordinary Shares attaining 4 pence or (ii) 12 months following First Admission or (iii) a takeover offer is announced for the Company. The reduction in the warrant exercise prices was agreed with all the warrant holders and from the Company's perspective, there will be a higher probability of receiving additional funding from the exercise of these warrants as the share price appreciates and the warrants are 'in the money'. |
thiopia - it's not nonsense at all.
I never said it was the ONLY way to fund a warrant exercise.
But it's more sensible & cheaper than any financial institution route, given IMM's current cash position. Especially as they can STILL retain a fair stake in Incanthera by exercising their warrants, whilst adding around £800k to their cash reserves. |
What is this nonsense about funding a warrant exercise ? There are plenty of financial institutions who could provide financing for it. |
Presumably today's sale of IMM's entire holding in Incanthera, netting c£1.5m is to fund the c7.3 million warrants at 9.5p before they expire on 6 September 2024?
7.3m Incanthera warrants would cost them around £694k. Assuming Incanthera's share price holds at around 20p, IMM can double their money on the warrants overnight & still have around £800k left over. |
 I wasn't aware of this - may be worth keeping an eye on for holders, although a good way from commercial release:
People with autoimmune disorders don’t usually get to talk about a cure. There’s symptom management, hopeful periods of remission often followed by relapses, but rarely a lasting fix for the way their immune system attacks healthy cells. If the immune system is an army, then those with conditions like lupus, multiple sclerosis, or rheumatoid arthritis are often fighting a never-ending war of friendly fire.
But over the last few years, researchers in Germany have begun testing the potential of CAR-T therapy — a cutting-edge cancer treatment in which a patient’s immune T cells are genetically modified in a lab to better attack disease targets — to help those with autoimmune disorders. Their latest findings, published Wednesday in the New England Journal of Medicine, provide evidence that has led experts to consider, tentatively, using the c-word.
In a study of 15 patients — eight with lupus, four with systemic sclerosis (scleroderma), and three with idiopathic inflammatory myositis, a rare muscle disease — researchers eliminated or reduced symptoms and disease biomarkers with a single infusion of CAR-T cells designed to target B cells, immune cells that play a key role in driving autoimmunity. There were no relapses among lupus patients, who were monitored for up to two years after treatment. The myositis and sclerosis patients, who had shorter-term follow-up (usually about three to six months but up to a year) saw their symptoms significantly lessen.
[...] |
Nobbyg-What do you consider is the time range for obtaining the patents mentioned in the last RNS? Do you think that this could adversely affect the time range for the Lupus trial commencing?
ATB |
The Incanthera direct holding must be worth gbp1.5m after todays rise plus 7.3m warrants which can be exercised anytime, so warrants presumably worth another gbp1.25m approx. This is what i call hidden value on the balance sheet. |
Good to see the rise for the LTHs here and the recent punters. It is somewhat ironic that the rise is due to the success of another company…but beggars can’t be choosers. |
Nice and quiet on here at moment, steady as she blows,when will all the Muppets arrive slagging it off lol GLA |
Money moving to APH [LSE] , excellent profitable healthcare company |
Still life in the old dog yet. |
stockriser - the announcement of no further dilution for now was, on the face of it, undoubtedly good news. It calmed market nerves & marked a turning point in share price direction.
That said, past pronouncements - notably from Tim M - have often proved unreliable. Also, any sale of IMM’s Incanthera holding would, in effect, just be dilution by the back door. Hopefully a commercial deal will come along before then to make this option unnecessary. |
...and it's worth reminding ourselves. This isn't a one-trick-pony. Many potential game changers in the pipeline. Multiple shots on goal. |
TI - Totally agree with you, Mcap is ridiculous for this Co., with so much potential and also as you say no further dilution. |
The Co. confirmed no further dilution. For me that calls the bottom. The upside here is huge. |
Many think this may drop back a bit so they can get in lower - Hmmm, not so sure myself.
GLA SR |
Me too, but trying to keep this under the RADAR. |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
